# 7 Pyridinyl alkyl 1,4 dihydro 4 oxo 3 quinolinecarboxylic acid having antibacterial activity and preparation thereof.

## Abstract
1 Ethyl 6 fluoro 1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 quin olinecarboxylic acid or salt thereof, a novel compound useful highly potent antibacterial agent with a broad spectrum of anti microbiai activity, is prepared by nitrating the corresponding 6 desfluoro compound to produce the corresponding 6 nitro compound, reducing the latter compound to produce the corresponding 6 amino compound and converting the 6 amino via its diazonium salt to said 6 fluoro compound. Said novel acid is also prepared via intermediates prepared by heating 4 2 fluorophenyl 2,6 dimethyl 3,5 pyridinedicarboxylic acid to produce a mixture of 4 2 fluorophenyl 2,6 di methylpyridine and 2,4 dimethyl 5H 1 benzopyrano 3,4 c pyridin 5 one, separating the components of said mixture and nitrating 4 2 fluorophenyl 2,6 dimethylpyridine to produce 4 2 fluoro 5 nitrophenyl 2,6 dimethylpyridine.

## Claims
CLAIMS 1. l Ethyl 6 fluoro l,4 dihydro 7 2, 6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylic acid of the formulaEMI53.1 or a pharmaceutically acceptable, non toxic acid addition or cationic salt thereof. 2. A process for preparing a compound according to claim 1, which comprises a. converting 6 amino l ethyl l ,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylic acid via its 6 diazonium salt to produce l ethyl 6 fluoro 1,4 dihydro 7 t2,6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylic acid or b. ethylating a 6 fluoro 1,4 dihydro 7 2,6 dimethyl4 pyridinyl 4 oxo 3 quinolinecarboxylic acid or loweralkyl ester thereof and in the case of the reaction with the lower alkyl ester thereby producing a lower alkyl ester of l ethyl 6 fluoro l,4 dihydro 7 2, 6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylic acid, hydrolyzing said ester to produce the corresponding acid, and, if desired, converting a free base obtained to an acid addition salt thereof or converting a compound obtained to a cationic salt thereof by reaction with a strong inorganic or organic base. 3. A process according to claim 2, in which in a., the 6 amino 1 ethyl 1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylic acid is prepared by nitrating l eEhyl 1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylic acid to produce l ethyl l,4 dihydro 7 2, 6 dimethyl 4 pyridinyl 6 nitro 4 oxo 3 quinolinecarboxylic acid, and reducing said 6 nitro compound. 4. A process according to claim 2, in which in b., the 6 fluoro 1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4oxo 3 quinolinecarboxylic acid is prepared by reducing 4 2 fluoro 5 nitrophenyl 2, 6 dimethylpyridine to produce 4 5 amino 2 fluorophenyl 2, 6 dimethylpyridine, reacting the latter compound of Example 6A with a di lower alkyl ethoxymethylenemalonate to produce a di lower alkyl 3 2,6 dimethyl 4 pyridinyl 4 fluoroanilinomethylenemalonate and refluxing the latter compound to produce a lower alkyl 6 fluoro 1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3quinolinecarboxylate, and, if the carboxylic acid is desired, hydrolyzing said lower alkyl carboxylate thus obtained. 5. A process for purifying l ethyl 6 fluoro l,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylic acid containing as impurities the corresponding 6 desfluoro and 6 hydroxy compounds by converting it to its corresponding lower alkyl l ethyl 6 fluoro1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 carboxylate, separating the ester from the reaction mixture and saponifying the ester to produce the purified acid. 6. A compound of the formulaEMI54.1 where Q is hydrogen or nitro, or an acid addition salt thereof. 7. A process for preparing a compound according to claim 6, which comprises heating 4 2 fluorophenyl 2,6dimethyl 3,5 pyridinecarboxylic acid to produce a mixture of 4 2 fluorophenyl 2, 6 dimethylpyridine and 2,4 dimethyl 5H l benzopyronof3,4 cZpyridin 5 one, separating the components of the mixture to isolate the 4 2 fluorophenyl 2,6dimethylpyridine and, if desired, nitrating the latter compound to produce 4 42 fluoro 5 nitrophenyl 2,6 dimethylpyridine. 8. A process for producing 4 2 fluoro 5 nitrophenyl 2,6 dimethylpyridine which comprises nitrating 4 2fluorophenyl 2,6 dimethylpyridine. 9. A composition for combatting bacteria which comprises an antibacterially effective amount of a compound according to claim 1 together with one or more pharmaceutically acceptable vehicles or excipients. 10. A method for combatting bacteria, which comprises contacting the locus of said bacteria with a compound according to claim 1. oC L A I M S 1. A process for preparing a 4 oxo 3 quiflo linecarboxylic acid of the formulaEMI56.1 or a pharmaceutically acceptable, non toxic acid addition or cationic salt thereof, characterized by a. converting 6 amino 1 ethyl 1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylic acid via its 6 diazonium salt to produce l ethyl 6 fluoro 1,4 dihydro 7 2, 6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxyiic acid or b. ethylating a 6 fluoro 1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylic acid or loweralkyl ester thereof and in the case of the reaction with the lower alkyl ester thereby producing a lower alkyl ester of 1 ethyl 6 fluoro 1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylic acid, hydrolyzing said ester to produce the corresponding acid, and, if desired, converting a free base obtained to an acid addition salt thereof or converting a compound obtained to a cationic salt thereof by reaction with a strong inorganic or organic base. 2. A process according to claim 1, in which in a., the 6 amino 1 ethyl 1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylic acid is prepared by nitrating 1 ethyl 1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3quinolinecarboxylic acid to produce l ethyl 1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 6 nitro 4 oxo 3 quinolinecarboxylic acid, and reducing said 6 nitro compound. 3. A process according to claim 1, in which in b., the 6 fluoro 1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylic acid is prepared by reducing 4 2 fluoro 5 nitrophenyl 2, 6 dimethylpyridine to produce 4 5 amino 2 fluorophenyl 2, 6 dimethylpyridine, reacting the latter compound of Example 6A with a di lower alkyl ethoxymethylenemalonate to produce a di lower alkyl 3 2,6dimethyl 4 pyridinyl 4 fluoroanilinomethylenemalonate and refluxing the latter compound to produce a lower alkyl 6 fluoro l, 4 dihydro 7 2, 6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylate, and, if the carboxylic acid is desired, hydrolyzing said lower alkyl carboxylate thus obtained. 4. A process for purifying l ethyl 6 fluoro 1,4 dihydro 7 2, 6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylic acid containing as impurities the corresponding 6 desfluoro and 6 hydroxy compounds characterized by converting it to its corresponding lower alkyl l ethyl 6 fluoro 1, 4 dihydro 7 2, 6 dimethyl 4 pyridinyl 4 oXo 3 carboxylate, separating the ester from the reaction mixture and saponifying the ester to produce the purified acid. 5. A process according to claim 4, where lower alkyl is ethyl. 6. A process for preparing a compound of the formulaEMI57.1 where Q is hydrogen or nitro, or an acid addition salt thereof, characterized by heating 4 2 fluorophenyl 2,6 dimethyl 3,5pyridinecarboxylic acid to produce a mixture of 4 2 fluorophenyl 2, 6 dimethylpyridine and 2,4 dimethyl SH 1 benzopyrono 3,4 c pyridin 5 one, separating the components of the mixture to isolate the 4 S2 fluorophenyl 2,6 dimethylpyridine and, if desired, nitrating the latter compound to produce 4 2 fluoro 5 nitrophenyl 2,6dimethylpyridine. 7. A process for producing 4 2 fluoro 5 nitrophenyl 2,6 dimethylpyridine characterized by nitrating 4 2fluorophenyl 2,6 dimethylpyridine.

## Description
This invention relates to a novel 7 pyridinyl l alkyl 1,4 dihydro 4 oxo 3 quinolinecarboxylic acid, salts thereof and its preparation, said compound having antibacterial use. British Patent 822,586, shows the nitration of l methyl 4 quinolone 3 carboxylic acid, alternatively named 1,4 dihydro 1 methyl 4 oxo 3 quinolinecarboxylic acid, by reacting it at room temperature with a nitrating agent comprising anhydrous nitric acid together with another anhydrous mineral acid, for example, sulfuric or phosphoric acid, to produce 1 methyl 6 nitro 4 guinolone 3 carboxylic acid, alternatively named 1,4 dihydro lmethyl 6 nitro 4 oxo 3 quinolinecarboxylic acid. British Patent 830,832 shows as antibacterial agents 1 alkyl 4 quinolone 3 carboxylic acids. Illustrative of compounds disclosed are l ethyl 6 nitro 4 quinolone 3 carboxylic acid Example 38 , which was prepared by nitrating 1ethyl 4 quinolone 3 carboxylic acid at room temperature with admixture of concentrated nitric acid and concen trated sulfuric acid and 1 ethyl 6 fluoro 4 quinolone 3 carboxylic acid Example 17 , alternatively named 1ethyl 1,4 dihydro 6 fluoro 4 oxo 3 quinolinecarboxylic acid, which was prepared by heating 3 ethoxycarbonyl6 fluoro 4 hydroxyquinoline with diethyl sulfate in aqueous sodium hydroxide solution. U.S. Patent 3,753,993 shows as antibacterial agents l a23l 114 dihydro 4 oxo 7 pyridinyl 3 quinolinecarboxylic acids. Illustrative of these compounds is l ethyl l,4dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylic acid Example 6A, also known as Win 35,439 , which was prepared stepwise as follows first reacting 4 3 aminophenyl 2,6 dimethylpyridine with diethyl ethoxy inethylenemalonate to produce diethyl 3 2,6 dimethyl 4 pyridinyl anilinomethylenemalonate Example 6B , next heating the latter in an eutectic mixture of diphenyl and diphenyl ether Dowtherm A to produce ethyl 1,4 dihydro 7 2 ,6 dimethyl 4 pyridinyl 3 guinolinecarboxylate Example 6C and then heating said ester with ethyl iodide in dimethylformamide in the presence of anhydrous potassium carbonate to produce the ethyl ester of l ethyl 1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3quinolinecarboxylic acid Example 6A , which is hydrolyzed to produce the corresponding acid.Also shown in this patent as Example 1A is l ethyl 1,4 dihydro 4 oxo 7 4 pyridinyl 3 quinolinecarboxylic acid, now known generically as rosoxacin and also as Win 35,213. U.S. Patent 3,907,808 shows as antibacterial agents 1 alkyl 1,4 dihydro 4 oxo 5 or 6 halo, lower alkyl or lower alkoxy 7 pyridinyl 3 quinolinecarboxy acids. Illus trative of these compounds is 7 3,5 dicarboxy 2,6 dimethyl4 pyridinyl 1 ethyl 6 fluoro 1,4 dihydro 4 oxo 3 quinolinecarboxylic acid Example 57A , which was prepared in six steps starting with 2 fluoro 5 nitrobenzaldehyde as follows 1 a mixture containing 2 fluoro 5 nitrobenzaldehyde, methyl acetoacetate, methanol and concentrated ammonium hydroxide was refluxed to produce dimethyl 4 2 fluoro 5 nitrophenyl 1,4 dihydro 2,6 dimethyl 3,5pyridinedicarboxylate Example 57B 2 oxidizing the product of Example 57B by heating it with 4N nitric acid to produce dimethyl 4 2 fluoro 5 nitrophenyl 2,6 dimethyl 3,5 pyridinedicarboxylate Example 57C 3 catalytically hydrogenating Example 57C to produce dimethyl 4 5 amino 2 fluorophenyl 2,6 dimethyl 3,5 pyridinedicar boxylate Example 57D 4 reacting Example 57D with diethyl ethoxymethylenemalonate to produce 3 3,5 dicarbomethoxy 2, 6 dimethyl 4 pyr idinyl 4 fluoroanilinomethylenemalonate Example 57E 5 heating Example 57E inDowtherm A to produce ethyl 7 3,5 dicarbomethoxy 2,6 dimethyl 4 pyridinyl 6 fluoro 1,4 dihydro 4 oXo 3 quino linecarboxylate Example 57F and, 6 heating Example 57F with ethyl iodide in dimethylformamide in the presence of anhydrous potassium carbonate and saponifying the resulting compound to produce 7 3,5 dicarboxy 2,6 dimethyl 4 pyridinyl l ethyl 6 fluoro l,4 dihydro 4oxo 3 quinolinecarboxylic acid Example 57A . Example 56F of this patent shows the conversion bf 4 2 metboxy 5 nitrophenyl 2,6 dimethyl 3.5 pyridinedicarboxylic acid to 4 2 methoxy 5 nitrophenyl 2,6 dimethylpyridine by heating it in Dowtherm A.Also, Example 64C shows the conversion of 7 3,5 dicarboxy 2,6 dimethyl 4 pyri dinyl 1 ethyl 1,4 dihydro 6 methyl 4 oxo 3 quinolinecar boxylic acid to 7 2,6 dimethyl 4 pyridinyl 1 ethyl l,4 dihydro 6 methyl 4 oxo 3 quinolinecarboxylic acid by heating it in diethyl phthalate at 240 255 C. U.S. Patent 4,146,719 shows as an antibacterial agent l ethyl 6 fluoro l, 4 dihydro 4 oxo 7 1 piperazinyl 3 quinolinecarboxylic acid, now known as norfloxacin, and its salts. U.S. Patent 4,292,317 shows as antibacterial agents 6 halo 1 substituted 7 substituted amino 1,4 dihydro 4 oxo 3 quinolinecarboxylic acids and salts thereof, including 1 ethyl 6 fluoro 1,4 dihydro 7 4 methyl 1 piperazinyl 4 oxo 3 quinolinecarboxylic acid, now known as pefloxacin. The present invention resides in l ethyl 6 fluoro 1,4 dihydro 4 oxo 7 2,6 dimethyl 4 pyridinyl 3 quinolinecarboxylic acids of the formula I. EMI5.1 and pharmaceutically acceptable, non toxic acid addition or cationic salts thereof. The compound of formula I and its said salts are useful as antibacterial agents, as determined by standard bacteriological evaluation procedures, Preferably the compound of formula I is in free base form. As shown hereinbelow, this compound is a highly potent antibacterial agent having a wide spectrum of activity against a wide variety of microorganisms, including anaerobic microorganisms associated with periodontal diseases. A composition for combatting bacteria comprises an antibacterially effective amount of l ethyl 6 fluoro 1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylic acid of formula I or a pharmaceutically acceptable non toxic acid addition or cationic salt thereof together with one or more pharmaceutically acceptable vehicles or excipients. A method for combatting bacteria comprises contacting the locus of said bacteria with a composition containing the compound of formula I or pharmaceutically acceptable non toxic acid addition or cationic salt thereof. One can produce the above compound of the invention by a. converting 6 amino l ethyl 1,4 dihydro 7 2,6 dbmethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylic acid via its 6 diazonium salt to produce l ethyl 6 fluoro 1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oXo 3 quinolinecarboxylic acid or b. ethylating a 6 fluoro 1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylic acid or lower alkyl ester thereof and in the case of the reaction with the lower alkyl ester thereby producing a lower alkyl ester of l ethyl 6 fluoro l,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylic acid, hydrolyzing said ester to produce the corresponding acid, and, if desired, converting a free base obtained to an acid addition salt thereof or converting a compound obtained to a cationic salt thereof by reaction with a strong inorganic or organic base.The complete sequence according to process a comprises nitrating l ethyl 1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylic acid to produce l ethyl 1,4 dihydro 7 2, 6 dimethyl 4 pyridinyl 6 nitro 4 oxo 3 guinoline carboxylic acid, reducing said 6 nitro compound to produce 6 amino l ethyl l,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 guinolinecarboxylic acid and convetting said 6 amino compound via its 6 diazonium salt to produce said l ethyl 6 fluoro l, 4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylic acid.In the reduction step, the preferred reducing agent is sodium hydrosulfite in an aqueous alkaline medium. A process for purifying l ethyl 6 fluoro l,4 dihydro 7 2 , 6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylic acid containing as impurities the corresponding 6 desfluoro and 6 hydroxy compounds comprises converting it to its corresponding lower alkyl 3 carboxylate, separating the ester from the reaction mixture and saponifying the ester to produce the purified acid. In the conversion of the corresponding 6 amino compound to the 6 fluoro compound of formula I, the conversion is preferably carried out by first preparing the 6 diazonium chloride, reacting it with hexafluorophosphoric acid, i,e., HPF6, to produce the corresponding 6 diazonium hexafluorophosphate, conveniently as its hydrofluorophosphate, and heated the latter to produce the 6 fluoro compound of formula I. In the purification process aspect of the invention, the ethyl 3 carboxylate is formed, isolated and saponified to produce the purified compound of formula I, The preferred process, according to process b , comprises heating 4 2 fluorophenyl 2,6 dimethyl 3,5pyridinedicarboxylic acid to produce a mixture of 4 C2 fuorophenyl 2,6 dimethylpyridine and 2,4 dimethyl 5E tl benzopyranof3,4 c pyridin 5 one, separating the components of said mixture, and nitrating the 4 2fluorophenyl 2,6 dimethylpyridine thus obtained to produce 4 2 fluoro 5 nitrophenyl 2,6 dimethylpyridine.As shown hereinbelow, 4 2 fluoro 5 nitrophenyl 2,6 dimethylpyridine is useful as an intermediate to prepare in very good yield the corresponding 4 5 amino 2 fluorophenyl 2, 6 dimethylpyridine which is converted in four steps all in very good yields to l ethyl 6 fluoro 1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oXo 3 quinolinecarboxylic acid. The overall process provides an improved and convenient means for preparing large scale quantities of said antibacterial agent. The invention further resides in a compound of the formula IIEMI8.1 where Q is hydrogen or nitro, or acid addition salt thereof. As noted above, these compounds are useful as key intermediates in the preparation of the highly potent antibacterial agent, 1 ethyl 6 fluoro 1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylic acid. The compounds of formulas I and II are useful both in the free base form and in the form of acid addition salts, and, both forms are within the purview of the invention.The acid addition salt is simply an alternative form for uset and in practice, use. of the salt form inherently amounts to use of the base form. The acids which can be used to prepare the acid addition salts of the compounds of fonmiks I and II include preferably those which produce, when combined with the free base, pharmaceutically acceptable salts, that is, salts whose anions are relatively innocuous to the animal organism in pharmaceutical doses of the salts, so that the beneficial antibacterial properties inherent in the free base are not vitiated by side effects ascribable to the anions.Appropriate pharmaceutically acceptable salts within the scope of the invention are those derived from mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid and sulfamic acid and organic acids such as lactic acid, acetic acid, citric acid, tartaric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p toluenesulfonic acid, cyclohexylsulfamic acid, suinic acid, and the like, givinq the hvrochloride, hydrobromide, sulfate. phosphate sulfamate, lactate, acetate, citrate, tartrate, methanesulfonate, ethanesul fdnate, benzenesulfonate, p toluenesulfonate, cyclohexylsulfamate and urinate, respectively. The acid addition salts of said compounds of forrtulas I and II are prepared either by dissolving the free base in aqueous or aqueous alcohol solution or other suitable solvents containing the appropriate acid and isolating the salt by evaporating the solution, or by reacting the free base and acid in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution. Other pharmaceutically acceptable salts of said compound of formula I are those cationic salts derived from strong inorganic or organic bases, e.g., sodium hydroxide, potassium hydroxide, trimethylammonium hydroxide, to produce the corresponding cationic salt, e.g., sodium, potassium, trimethylammonium salt, respectively. Although pharmaceutically acceptable salts of said basic compounds of formula II is preferred, all acid addition salts are within the scope of the inO39 All acid addition salts are useful as sources of the free base form even if the particular salt per Se is desired only as an intermediate product as for example when the salt is forme only for purposes of purification or identification, or when it is used as an intermediate in preparing a pharmaceutically acceptable salt bv ion exchange procedures.I The molecular structure of the compounds of formula I and corresponding intermediate 6 nitro and 6 amino compounds and of the compounds of formula II were assigned on the basis of evidence provided by infrared, ultraviolet, nuclear magnetic resonance and mass spectra, by the correspondence of calculated and found values for the elemental analyses, and by their method of preparation. The manner of making and using the instant invention will now be generally described so as to enable a person skilled in the art of pharmaceutical chemistrv to make and use the same. The nitration of the known 1 ethyl 1,4 dihydro 7 2,6 dimethyl 4 pyridinvl 4 oxo 3 quinolinecarboxylic acid U.S. Patent 3,753,993 to produce the corresponding 6 nitro compound was carried out by reacting said known compound with concentrated nitric acid in the presence of concentrated sulfuric acid, the reaction carried out by first mixing the reactants at ambient temperaturs and then heating the reaction mixture at about 90 C. to 110 C., conveniently on a steam bath. The product was obtained by pouring the cooled reaction mixture into excess ice water and partially neutralizing to a pH of about 5.5 to 6.0 the aqueous acidic solution with concentrated ammonium hydroxide and collecting the precipitated 6 nitro compound. The conversion of l ethyl 1,4 dihvdro 7 12,6 di methyl 4 pyridinvl 6 nitro 4 oxo 3 quinolinecarboxvlic acid to the corresponding 6 amino compound was conveniently carried out by heating the 6 nitro compound at about 9O0C. to 1100C., conveniently on a steam bath, with sodium hydrosulfite also named sodium dithionite in an aqueous alkaline medium containing an organic solvent, e.g . dimethylformamide, sodium bicarbonate conveniently used to make the solution alkaline. The 6 amino compound was isolated by acidifying the cooled reaction mixture to a pH of about 5.5, preferably with acetic acid, and collecting the precipitated 6 amino compound.Alternatively, the reduction of the 6 nitro compound to the corresponding 6 amino compound can be carried out by catalytic hydrogenation using palladium on charcoal as catalyst and acetic acid as solvent. The conversion of 6 amino l ethyl 1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylic acid to the corresponding 6 fluoro compound was done by first preparing the 6 diazonium salt, preferahly chlor ide, treating its aqueous solution at about 100C. using an ice salt bath with hexafluorophosphoric acid carefully added in one portion , collecting the precipitated 6 diazonium hexafluorophosphate as its hydrohexafluorophosphate, heating the diazonium salt at about 2000C.to 2400C., preferably about 2250C. to 2350C., in a suitable solvent, e.g., paraffin oil, dissolving the cooled reaction mixture with aqueous ammonium hydroxide e.g., 5N , filtering the solution and slightly acidifying to a pH of about 5.5 the filtrate with acetic acid and collecting the precipitated 6 fluoro compound of formulaI , which contained about 10 15 of the 6 desfluoro compound produced during decomposition of the diazonium salt and a trace of the corresponding 6 hvdroxy compound.The 6 fluoro compound was separated from said impurities by converting it to its lower alkvl, preferably ethvl, ester, separating the ester from the correspondinq ester of the 6 desfluoro compound and of the 6 hydroxy compound by high pressure liquid chromatography and then saponifying the ester to produce the purified 6 fluoro acid of formula I. As shown hereinbelow in Example 3, the intermed irate 4 2 fluoophenyl 2,6 dimethyl 3,5 pyridinedicar boxylic acid used in process b, was arepund in very good yield by first adding g concentrated aqueous ammonia to a mixture of 2 fluorobenzaldehyde and methvl acetoacetate in methanol to produce dimethyl 4 2 fluorophenyl l,4 dihyro 2,6 dimethyl 3,5 pyridinedicarboxylate, oxidizing the 1,4 dthydro compound with 4N nitric acid to produce dimethyl 4 2 fluorophenyl 2,6 dimethyl 3,5 pyridinedicarboxylate and saponifying the latter ester by heating it with sodium hydroxide in aqueous methanol at about 60 650C. to produce 4 2 fluorophenyl 2,6 dimethyl 3,5 pyridinedi carboxylic acid. Decarboxylation of 4 2 fluoropyhenyl 2,6 dimethyl3,5 pyridinedicarboxylic acid to produce 4 2 fluorophenyl 2,6 dimethylpyridine was carried out conveniently by heating the dicarboxylic acid at about 2400C. to 3000C., preferably about 240 255 C., in a suitable high boiling solvent, preferably by refluxing said dicarboxylic acid in a eutectic mixture of diphenyl and diphenyl ester Dowtherm A whereupon there resulted in the formation of 4 2 fluorophenyl 2,6 dimethylpvridine and varying amounts of 2,6 dimethyl 5H 1 benzopyrano 3,4 c pyridin5 one as a side product, filtering off the side product from the cooled reaction mixture and then isolating the desired product. After removal of the side product, the desired product is isolated from the remaining reaction mixture by extracting it with an aqueous mineral acid, preferably HCl, making the acidic extract alkaline, preferably with aqueous ammonia, and extracting the prod uct with a suitable solvent such as chloroform, ether or methylene dichloride. Other high boiling solvents that can be used in place of Dowtherm A are mineral oil, dimethyl phthalate and the like. In using the preferredDowtherm A, it was found that a greater proportion of the desired 4 2 fluorophenyl 2,6 dimethylpyridine and a lesser amount of the said side product were obtained by using a larger quantity of Dowtherm A. Use of recycled or previously used Dowtherm A decreased the yield of desired product. The conversion of 4 2 fluorophenyl 2,6 dimethylpyridine to 4 2 fluoro 5 nitrophenyl 2,6 dimethylpyri dine was carried out bv adding a molar equivalent auantitv or slight excess of a metal nitrate. preferably potassium nitrate, to 4 2 fluorophenyl 2,6 dimethylpyridine in excess concentrated sulfuric acid, keeping the reaction temperature below about 0 C., preferably between about 100C. to 15 C., conveniently accomplished using an salt ice bath. Alternatively, other alkali metal or alkaline earth metal nitrates, e.g., sodium nitrate or calcium nitrate, can be used in place of potassium nitrate. As illustrated hereinbelow in Example 6, 4 2 fluoro 5 nitrophenyl 2,6 dimethylpyridine is converted to l ethyl 6 fluoro 1,4 dihydro 7 2 ,6 dimethYl 4 pYri dinyl 4 oxo 3 quinolinecarboxylic acid in very good yield by first reducing 4 2 fluoro 5 nitropbenyl 206 dimethylpyridine by catalytic hydrogenation to produce 4 5 amino 2 fluorophenyl 2,6 dimethylpyridine, alterna tively named 3 2,6 dimethyl 4 pyridinyl 4 fluorobenzene amine Example 6A , reacting the 5 amino 2 fluorophenyl compound of Example 6A with a di lower alkyl diethyl ethoxymethylenemalonate EMME to produce a di lower alkyl diethyl 3 2,6 dimethyl 4 pyridinyl 4 fluoroanilinomethylenemalonate Example 4B , refluxing the EMME adduct of Example 6B in Dowtherm A to produce a lower alkyl ethyl 6 fluoro l,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylate Example 6C , ethylating the compound of Example 6C by heating it with an ethylating agent, that is, the ethyl ester of an inorganic acid or a strong organic acid, e.g., ethyl iodide, in dimethylformamide in the presence of anhydrous potassium carbonate to produce ethyl l ethyl6 fluoro 1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4oxo 3 quinolinecarboxylate Example 6D and hydrolyzing the compound of Example 6D by refluxing it in aqueous sodium hydroxide solution containing methanol to produce l ethyl 6 fluoro 1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4oxo 3 quinolinecarboxylic acid Example 6E .Although the carboxylate is ethylated according to the above preferred procedure, it is also possible to hydrolyze the lower alkyl ester obtained by Example 6C and ethylate the resulting acid under substantially the same conditions for said respective corrosion steps. The following examples will further illustrate the invention without limiting it thereto. Example 1A. 1 Ethyl 1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 6 nitro 4 oxo 3 quinolinecarboxvlic Acid To a stirred solution containing 200 g. of 7 2,6 dimethyl 4 pvridinyl l ethyl 1,4 dihydro 4 oxo 3 quinolinecarboxylic acid in 440 ml of 95 98 H2SO4 was added a solution of 80 ml of 90 HNO3 in 80 ml of 95 98 H2SO4 over a period of one hour. The resulting solution was stirred at room temperature for an additional 20 minutes, then heated on a steam bath for 8 hours. The reaction mixture was allowed to stand at room temperature overnight and then poured into 6000 ml of ice water. The precipitate was collected and slurried in approximately 2000 ml water.Concentrated NH4OH was added to reach a pH of 5.5 6.0.The solid was collected and washed with a small amount of ethanol and ether. Additional material was obtained by treating the original filtrate with NH4OH as described above. Recrystallization from dimethylformamide aave several crops totalling 135 g 59 and melting from 2740C. to 298 C. A 2.8 g sample was recrystallized from 20 ml of dimethylformamide, washed with ether and dried at 1200C. for 16 hours at 0.02 mm to produce 1.54 g of l ethyl l,4 dihydro 7 216 dimethyl 4 pyridinyl 6 nitro 4 oxo 3 quinolinecarboxylic acid, m.p. 289 2910C. B. 6 Amino 1 ethyl 1,4 dihydro 7 2,6 dimethyl 4 pyridinvl 4 oxo 3 guinolinecar.boxylic Acid A 35 g portion of 1 ethyl 1,4 dihydro 6 nitjro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylic acid was suspended in a mixture of 350 ml of hot dimethylformamide, 280 ml of saturated NaHCO3 and 70 ml of water and the suspension was heated on a steam bath with stirring.A mixture of 58 g of sodium hydrosulfite in 100 ml of water was added in portions over a period of 20 minutes, during which time the reaction mixture became a clear solution and then darkened. More saturated NaHCO3 solution 50 ml was added and the reaction mixture was heated for 16 hours, after which time reduction was not complete.More sodium hydrosulfite 12 g was added directly to the reaction mixture and heating continued for 1 hour after which time the reduction appeared to be complete byTLC . Water 100 ml was added, redissolving some of the material which had come out of solution and, the mixture was heated an additional 90 minutes to insure completion of the reduction. A 1.15 g sample, m.p. 288 290CC. with decomposition, was recrystallized from ethanol and dried for 16 hours at 1300C. under high vacuum to yield 0.9 g of 6 amino 1 ethyl 1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylic acid as its monohydrate, m.p. 3000C. C. 3 Carboxv l ethyl l,4 dihvdro 7 2,6 dimethvl 4 pyridinyl 4 oxo 6 quinolinyldiazonium Hexafluorophosphate A 20 g portion of 6 amino l ethvl l,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylic acid monohydrate was suspended in 100 ml of 6N HC1 and placed in an ice salt bath. When the temperature of the mixture had reached 100C., a cold solution of 4.5 g of NaNO2 in 20 ml of B20 was added in portions over a period of a few minutes. The reaction mixture was stirred for 5 10 minutes during which time it became a clear solution.Hexafluorophosphoric acid 18 ml was carefully added in one portion whereupon a Drecip itate separated immediately, the temperature rising to 0 C. before dropping again. The reaction mixture was stirred for 30 minutes after addition and, then the precipitate was collected and washed successively with water, a small volume of cold ethanol, and finallv with ether. The product was vacuum dried at 5O0C. for 48 hours in the presence of P2O5 to give 29.7 g 78 of 3 carboxy 1 ethyl 1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 6 quinolinyldiazonium hexafluorophosphate as its hydrohexafluorophosphate, m.p. 200 2050C. with decompo sition. D. l Ethyl 6 fluoro l,4 dihvdro 7 26 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylic Acid A 19.6 g portion of the diazonium salt of Example 3 was placed in a 3 necked round bottom flask equipped with a mechanical stirrer and connected to a nitrogen aPDaratus. Paraffin oil 200 ml was added, the apparatus evacuated and filled with nitrogen. The reaction vessel was then immersed in an oil bath preheated to 2300C. After 10 minutes the starting material gummed up and formed a ball, making stirring difficult. After heating for a total of 25 minutes the hot oil was decanted and the reaction mixture allowed to cool. It was then washed with n hexane, broken up with a pestle and dissolved in 5N NH40H approximately 900 ml . This solution was filtered through a pad of diatomaceous earth and the filtrate acidified to a pH of 5.5 with concentrated acetic acid.After being refrigerated overniqht, the precipitate the 6 fluoro compound was collected and found to contain a trace of the corresponding 6 hydroxy compound evidence MS and 10 158 of the correspondng 6desfluoro compound evidence NMR . Recrystallization from dimethylformamide yielded a first crop of 4.4 g 43 and a second crop of 1.5 g 15 . Products from several runs were combined and after two recrystallizations from DMF still contained approximately 108 of the 6 desfluoro compound. This compound was ultimatelv purified Example 2 by converting it to the ethyl ester, separating it from the 6 desfluoro ethyl ester bv high pressure liquid chromatography, then saponifying it back to the acid. Example 2A. Ethyl l Etbvl 6 fluoro l, 4 dihydro 2,6 dimethvl 4 pvridinyl 4 oxo 3 quinolinecarboxylat A 12.3 g sample of the 6 fluoro compound containinq about 102 of the 6 desfluoro compound i.e., the final product of Example lD and another 12.2 g of the same 6 f luoro compound obtained from mother liquors of other runs and of varying purity were converted to 14.8 q of ethvl ester by refluxing for 48 hours in 1N ethanolic SC1 containing a small quantity of triethyl orthoformate to take up any traces of water present In a typical example 600 ml iN ethanolic HCl and 3 ml triethyl orthoformate were used for 5.0 g of fluoro acid .The 14.8 g of ester was purified by preparative NPLC using a solvent system of 60 acetone 40 hexane to give 8.3 g of pure 6 fluoro ester, i.e., ethyl l ethyl 6 fluoro 1,4 dihvdro 7 ,S dimethyl 4 pyrioinyl 4 oxo 3 quinolinecarboxylate, which was used directly in the next step Example 2A .B. 1 Ethyl 6 fluoro 1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylic Acid To 8.39 of the ethyl ester of Example 2A was added 200 ml of water and 1.8 g of sodium hydroxide. The mixture was heated on a steam bath for 3 and 1 2 hours, after which hydrolysis was incomplete. NaOH 0.9 g3 was added and heating continued for 16 hours. The hot reaction mixture was filtered and the filtrate allowed to cool, after which it was acifified to a tH of 5 5.5 with concentrated acetic acid. The precipitate was collected and washed successively with water, ethanol and ether.The product was recrystallized from dimethylformamide to yield 6.7 q 888 of l ethyl 6 fluoro l,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 qunolinecarboxylic acid, m.p. 300 C. Example 3A. Dimethyl 4 2 fluorophenyl l,4 dihydro 2,6 dimethyl 3,5 pyridinedicarboxylate To a stirred solution containing 119 g of 2 fluorobenzaldehyde, 600 ml of methanol and 255 ml of methyl acetoacetate was added 200 ml of concentrated ammonium hydroxide whereupon an exothermic reaction ensued. The reaction mixture was stirred at ambient temperature for 30 minutes, next refluxed a few hours and then allowed to stand at room temperature overnight about 15 hours .The yellow solid that crystallized was collected, washed with ether and dried in an oven at 50 600C. to yield 201 g of dimethyl 4 2 fluoro phenyl 1,4 dihydro 2,6 dimethyl 3,5 pYridinedicarboxylate, m.p. 206 2080C. Concentration of the mother liquor yielded another 26.4 g of the product, m.p. 204 2060C. The total yield was 74 . Dimethvl 4 2 fluorophenyl 2,6 dimethvl 3,5 pyri dinedicarboxylate To 600 ml of 90 nitric acid heated to about 700C. was added with, stirringover a period of 20 minutes 302.9 g of dimethyl 4 2 fluorophenyll 1,4 dihydro 2,6 dimethyl 3,5 pyridinedicarboxylate. The reaction mixture was heated on a steam bath for 1 hour and then allowed to cool with stirrinq for 2 hours.The reaction solution was then chilled and made basic with ammonium hydroxide solution. The resulting precipitate was collected, washed with water and dried in a vacuum oven at 750C. to yield 302.8 g of yellow solid.The solid was slurried in water, collected, washed with water and dried in a vacuum oven at 650C. to yield 273.7 g 90 of product, m.p. 85 880C., which was used directly in the next step Example 1C . A 20 g sample of the product was dried at 700C., recrystallized from n hexane and dried in a vacuum oven at 650C. to yield 15.9 g of dimethyl 4 2 fluorophenyl 2,6 dimethyl 3,5 pyridinedi carboxylate, m.p. 94 960C. C. 4 2 FluoroPhenyl 2.6 dimethYl 3,5 Pyridinedicar boxylic Acid A mixture containing 69 g of dimethyl 4 2 fluorophenyl 2,6 dimethyl 3,5 pyridinedicarboxylate, 300 ml of methanol and 100 ml of 35 aqueous sodium hvdroxide solution was refluxed with stirring for 5 hours and then allowed to stand at room temperature overnight.The methanol was removed usinq a rotarv evaporator and to the residual liquid was added 200 ml of water and filtered. The filtrate was acidifed with concentrated hydrochloric acid whereupon there precipitated a cream colored solid, which was washed with water and dried at 80 850C. to yield 52.6 g 88 of 4 2 fluorophenyl 2,6 dimethyl 3,5 pyridinedicarboxylic acid, m.p. 2850C. F.xamPle4 4 2 Fluorophenyl 2,6 dimethylpyridine To 1400 ml of Dowtherm A heated to 240 2450C. was added over a 10 minute period 113 g of 4 2 fluorophenyl 2,6 di methyl 3,5 pyridinedicarboxylic acid and the reaction mixture was boiled for 50 minutes, cooled and allowed to stand at room temperature overnight. The crystalline solid, a by product identified below, was filtered off and the filtrate was extracted with 700 ml of 3N hydro choloric acid followed by a second extraction with 300 ml of 3N hydrochloric acid. The combined acidic extracts were made basic by adding aqueous ammonium hydroxide and the alkaline mixture was extracted with 800 ml of chloroform.Evaporation of the chloroform yielded a brown mixture of solid and liquid, to which was added 300 ml of n hexane and the mixture chilled. The solid was filtered off and dried. This solid, a by product, was combined with the above noted solid by product to yield 25.4 g 29 of 2,4 dimethyl 5H 1 benzopyrano 3,4 c pyridin 5 one. m.p. 194 197 C. The filtrate was concentrated to dryness on a steam bath, the residue taken up with ethanol and the solution concentrated on a rotary evaporator to yield, as a liquid, 55.2 g 70 of 4 2 fluorophenyl 2,6 dimethylpyridine. In another run as in the preceding paragraph using 113 g of 2 2 fluorophenyl 2,6 dimethyl 3,5 pyridinedi carboxylic acid, 1.1 liter of recovered Dowtherm A used in a previous run filtered through diatomaeous earth plus 300 ml of fresh of Dowtherm A, there was obtained 28.4 g 328 of by product, 2,4 dimethyl SH tljbenzo pyrano 3,4 c pyridin 5 one, m.p. 193 196 C. and 44.8 g 57 of 4 2 fluorophenyl 2,6 dimethylpyridine in free base form as a liquid. In another run using a smaller proportionate amount of Dowtherm A, that is, 1200 ml, and 200 g of 4 2 fluorophenyl 2,6 dimethyl 3,5 pyridinedicarboxylic acid. there was obtained a greater proportionate amount of said byproduct, namely 57 g 36.7 of 2,4 dimethyl 5H 1 benzo pyranof3,4 c pyridin 5 one and 42 g 30 of 4 2 fluorophenyl 2,5 dimethylpyridine in free base form. The above three batches of by product, were combined, recrystallized from methanol and dried at 70 750C. to yield 141 g of 2,4 dimethyl 5H 1 benzopyrano ,4 c pyridin 5 orie, m.p 204 207 C. The above three batches of 4 2 fluorophenyl 2,6 dimethylpyridine were combined and mixed well with 400 ml of n hexane and 600 ml of 3N aqueous hydrochloric acid. The aqueous layer was separated, treated with decolorizing charcoal and concentrated to dryness on a rotary evaporator to give a white solid residue, about 9 g of which was recrystallized from isopropyl alcohol and dried over P205 at room temperature to yield 7.8 g of 9 2 fluorophenyl 2,6 dimethylpyridine hydrochloride hemihydrate, m.p. 200 2030C. The remainder of the solid residue was dissolved in 700 ml of water, the solution made basic with aqueous ammonium hydroxide and the resulting alkaline solution extracted twice with 500 ml portions of chloroform.Removal of the chloroform yielded 148 g of 4 2 fluorophenyl 2,6 dimethylpvridine in free base form as a light brown liquid, which was used in the next step Example 5 . Example 5 4 2 fluoro 5 nitrophenyl 2,6 dimethylpyridine To 55 ml of concentrated sulphuric acid cooled in a saltice bath to about 10 to 150C. was added 10.1 g of potassium nitrate over a 5 minute period. The mixture was allowed to stir for 10 minutes and then to it was added dropwise over a 30 minute period 18.5 g of 4 2 fluoro phenyl 2,6 dimethylpyridine whereupon a gummy solid separated and a viscous slurry was obtained, the reaction temperature rising to about OOC. In order to facilitate stirring, another 50 ml portion of concentrated sulphuric acid was added dropwise over a 15 minute period and the resulting mixture was stirred in the salt ice bath and then stirred for a period of about 5 hours while allowinq the temperature of the reaction mixture to rise to room temperature. The reaction mixture was poured onto a large excess of ice and the mixture was neutralized by adding aqueous ammonium hydroxide solution. The resulting light yellow fluffy precipitate was collected, washed with water and air dried. The solid was then dissolved in 300 ml of chloroform, the solution treated with decolor izing charcoal and filtered.The filtrate was concentrated on a rotary evaporator and the residue was stirred with 200 ml of 1 1 ether n hexane, the mixture filtered and the collected solid dried at 70 75 C. to vield 18.67 g 84 of 4 2 fluoro 5 nitrophenyl 2,6 dimethylpyri dine, m.p. 169 1710C. Example 6 A. 3 2,6 dimethyl 4 pyridinyl 4 fluorobenzeneamine 4 2 fluoro 5 nitrophenyl 2,6 dimethylpyridine, 180 g, was divided into four equal portions and each portion was reduced separately as follows. A mixture containing 45 g of 4 2 fluoro 5 nitrophenyl 2,6 dimethylpyridine, 200 ml of acetic acid and 800 ing of platinum dioxide was catalytically hydrogenated until hydrogen uptake ceased, about 4 hours with little hydrogen uptake the last thirty minutes. The catalyst was filtered off, washed with 300 ml of water, and the filtrate made sic by adding aqueous ammonium hydroxide. The solution was cooled to yield a oily material which solidified. The solid was collected, washed with water and dried to yield the desired amine.The remaining three. 45 g portions of 4 2 fluoro 5 nitrophenyl 2,6 dimethylpyridine were reduced in the same way and the combined amine products were dissolved in 600 ml of concentrated hydrochloric acid and heated on a steam bath with stirring for 4 and 1 2 hours and then treated with decolorizing charcoal and filtered. The filtrate was made basic by adding aqueous ammonia and the resulting mixture was chilled to yield an oil which crystallized. The crystalline material was collected, washed with water and dried in an oven to yield 164.9 g of gummy solid. The solid was dissolved in ether containing 5 methanol and the solution was filtered through silica gel to remove the gummy impurities.The ether methanol solvent of the filtrate was distilled off in vacuo and the residue was recrystallized from ether isopropyl alcohol to yield 80.9 g of 3 2.6 dimethyl 4 pyridinyl 4 fluorobenzeneamine, m.p. 142 1450C. Concentration of the mother liquor yielded another 43.4 g of the product, m.p. 141 1440C., thereby giving a total yield of 82 .B. Diethyl 4 fluoro 3 2,6 dimethvl 4 pvridinvl ani linomethylenemalonate A mixture containing 122 g of 3 2,6 dimethyl 4 pyridinyl 4 fluorobenzeneamine, 130 g of diethyl ethoxymethylenemalonate and 120 ml of toluene was heated with stirring at 130 1350C. for 3 and 1 2 hours using an air condenser allowing ethanol to escape from the reaction mixture. The reaction mixture was cooled and dissolved in one liter of boiling n hexane.The hot solution was filtered through diatomaceous earth, the pad washed with hot n hexane 400 ml , and the combined filtrate and washings were allowed to stand at room temperature for 18 hours. The white crvstalline solid that separated was collected, washed with n hexane and dried at 60 65 C. to yield 159.6 q 74 of diethyl 4 fluoro 3 2 ,6 dimethyl 4 pyr idinyl anilinomethylene malonate, m.p. 99 1000C. Another 67 g of the crude product was obtained from the mother liquor and was cyclized without further purification as in the following Example 4C to yield 35.2 g of the product of Example 4C m.p. 3000C. .C. Ethyl 6 Fluoro 1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylate To a 1300 ml of boiling Dowtherm A in a two liter Erlenmeyer flask wrapped with aluminum foil to maintain the temperature of theDowtherm A at about 260 265 C. was added 154 g of diethyl 4 fluoro 3 2,6 dimethyl 4 pyridinyl anilinomethylenemalonate over a 5 minute period. The same reaction temperature was maintained for about 20 minutes and then the reaction mixture was allowed to cool. The precipitated tan solid was collected, washed successively with ether and ethanol and dried at 90 950C. to yield 107.4 g 79 of ethyl 6 fluoro 1,4 dihydro 7 2,6 dimethyl 4 pvridinyl 4 oXo 3 quinolinecarboxylate, m.p. 3000C. D. Ethyl 1 Ethyl 6 fluoro 1,4 dihydro 7 2,6 dimethyl4 pyridinyl 4 oxo 3 quinolinecarboxylate A mixture containing 34 g of ethyl 6 fluoro 1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylate, finelv divided anhydrous potassium carbonate and 250 mi of methylformamide was heated with stirring on a steam bath for 20 minutes and then 9 ml of ethyl iodide was added over a 20 minute period. The reaction mixture was heated on a steam bath with stirring for 2 and 1 2 hours and then concentrated to dryness on a rotary evaporator.The residue was shaken well with 300 ml of water and 500 ml of chloroform. The layers were separated and the aqueous layer was extracted with another 200 ml portion of chloroform. The combined chloroform extracts were concentrated in vacuo to remove the chloroform. The remaining solid was dissolved in 150 ml of hot isopropyl alcohol. the hot solution treated with decolorizing charcoal and filtered. The filtrate was concentrated on a rotary evaporator to a volume of about 50 ml which was diluted with ether until turbid. The mixture was allowed to cool and the separated crystalline solid was collected, washed with ether and dried at 80850C. to yield 18.5 g of ethyl l ethyl 6 fluoro l,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylate, m.p. 221 2240C. Further concentration of the mother liquor yielded another 3.4 g 60 of product, m.p. 220 2230C. A larger run 0.3 mole scale gave the above compound, m.p. 222 2250C., in 80 yield. E. 1 Ethyl 6 fluoro 1,4 dihydro 7 2,6 dimethyl 4 pyridinyi 4 oxo 3 quinolinecarboxvlic Acid A mixture containing 98 g of ethyl l ethyl 6 fluoro l,4 dihydro 7 f2,6 aimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylate, 50 ml of 35 aqueous sodium hydroxide solution, 500 ml of water and 100 ml of methanol was refluxed with stirring for 90 minutes and the resulting brown solution was acidified with acetic acid whereupon a light yellow precipitate separated.The mixture was allowed to stand at room temperature for about 2 hours and the precipitate was collected, washed successively with water and ethanol and then dried at 90 95 C. to yield 86.8 g 95 of 1ethyl 6 fluoro 1,4 dihydro 7 2,6 dimethyl 4 pyridinyl 4 oxo 3 quinolinecarboxylic acid, m. . 3100C. The usefulness of l ethyl 6 fluoro 1,4 dihydro 7 26 dimethyl 4 pyridinyl 4 oxo 3 quinolinecaLboxylic acid compound of formula I and of Samples 2B and 6E Which is designated hereinbelow as Win 52,522 and its uniqueness as a highly potent antibacterial agent having a broad spectrum of antimicrobial activity have been demonstrated by the following experiments. Experiment 1COMPARATIVE IN VITRO ANTIBACTERIAL ACTIVITY OF WIN 52.522, WIN 35.439, METHICILLIN AND VANCOMYCIN As noted above, Win 52.522 is the compound of formula I, i.e., the compound of Example 2B hereinabove.Win 35,439 is its 6 desfluoro analog. Methicillin, used as its sodium salt TEE MERCK INDEX, 10th End,, 5842 , is 6 2,6 dimethoxybenzamido penicillanic acid sodium salt. Vancomycin, used as its hydrochloride THE MERCKINDEX, 10th Ed., 9731 , is an amphoteric glycopeptide antibiotic.Summary Win 52,522 MIC values 0.008 to 0.5 mcq mll was 2 8 times more potent in vitro than Win 35,439 aqainst several Gram positive cocci. includinq S. aureus, S. pidermidis and Streptococcus species. Win 52,522 was 32 to 8000 times more potent, and 16 to 125 times more potent, in vitro than methicillin and vancomycin, respectively, against the Staphylococcus species. Win 52,522 was 2 to 8 times less potent than methicillin againstS. pyogenes and S. pneumoniae, but was 32 to 500 times more potent than methicillin against S. faecalis. Win 52,522 was bactericidal MBC MIC 4 for all 39 bacterial test strains.Introduction This study was designed to determine the comparative in vitro antibacterial activity of Win 52,522, Win 35,439, methicillin and vancomycin against strains of Staphylococcus and Streptococcus. Escherichia coli and Pseudomonas aeruginosa test strains were also examined to illustrate the Gram negative potency of Win 52,522 relative to that of Win 35,439. Compound Preparation Win 52,522 and Win 35,439 were solubilized in 0.1 ml of 0.5 N NaOR mg of compound and diluted in sterile distilled water to 160 mcg ml. Vancomycin and methicillin were solubilized in sterile distilled water to 1250 mcq ml of base compound. The stock solutions were sterilized by filtration through membrane filters with a 0.45 um pore size.Media Mueller Hinton broth MHB BBL Mueller Hinton agar MHA BBL Brain Heart Infusion BHI broth Difco Brain Heart Infusion BHI agar Difco Normal horse serum NHS GibcoBacterial Cultures The bacterial cultures listed inTable I hereinbelow were grown overnight at 370C. inMHB for all cultures except the Streptococcus strains.These were grown in BHI 10 NHS. The overnight broth cultures were adjusted to an optical density of 0.10 650 nm, B L Spectronic 20 in sterile distilled water and subsequently diluted to 6.7 x 106 cells ml in MH or BHI 1 NHS.Minimal Inhibitory Concentration MIC Test Serial two fold dilutions of the compound solutions were prepared in MHB or in BRI 1 NHS for tests with StrePto cocci and dispensed into 96 well microtiter travs in a volume of 0.1 ml well using a Sandy Springs Bellco Glass Co. dispenser. The trays were then inoculated with 0.0015 ml of a suspension containing 6.7 x 106 cells ml of the appropriate inoculum using a MIC 2000 inoculator Dynatech Corp. resulting in a final inoculum of approximately I x 104 cells well or 1 x 105 cells ml.The trays were incubated at 370C. for 18 20 hours and the minimal inhibitory concentration MIC , defined as the lowest concentration of compound to inhibit visible bacterial growth, was recorded.Minimal Bactericidal Concentration MBC Test After the MIC values were recorded, the contents in the microtiter trays were thoroughly mixed on a Bellco Mini orbitalShaker Bellco Glass Co. for 3 min at a setting of 8. A portion 0.0015 ml from each well was then transferred via an MIC 2000 inoculator to Plates containingMHA or BRI agar 10 NHS. The plates were incubated at 370C. for 18 20 hrs. The minimal bactericidal concentration MBC , defined as the lowest concentration of compound that prevented the formation of a recoqnizable colony on the agar surface, was recorded.RESULTS AND DISCUSSION The individual test results are shown in Table 1 and in summary form in Table 2. TABLE 1 IN VITRO ANTIBACTERIAL ACTIVITY OF WIN 52,522, WIN 35.419, AND VANCOMTCIN WIC and MDC VALUES in mag ml WIN 52,522 Win 35,414 MET LIN V MYCIM Bacteria MIC MBC MIC Mia M M M M S. pureus 13 8 A 0.03 0.03 0.06 0.125 1 2 0.5 0.5 4 81 0.015 0.03 0.06 0.125 2 2 0.5 0.5 24 81 0.015 0.03 0.06 0.125 1 2 0.5 0.5 34 81 0.03 0.03 0.06 0.06 1 2 0.5 0.5 41 81 0.015 0.015 0.06 0.25 1 1 1 1 21 81A 0.015 0.015 0.06 0.125 1 1 0.5 1 S 214 0.015 0.03 0.06 0.125 8 12 1 1 S 500 0.03 0.06 0.125 0.25 8 12 1 1 10 81 0.03 0.03 0.125 0.125 8 16 1 1 59 81 0.015 0.03 0.125 0.25 12 4 1 1 39881 0.015 0.03 0.06 0.06 125 125 1 1 Smith 0.01 0.03 0.125 0.125 1 1 1 1 1259231 0.015 0.01 0.125 0.125 2 2 1 1 Glorgio 0.000 0.015 0.03 0.125 2 4 1 1 VA16951 0.015 0.015 0.06 0.06 4 8 1 1S. epidermidis 12228 0.06 0.06 0.25 0.25 4 4 1 1 17917 0.06 0.125 0.5 0.5 4 4 1 1 ATCC No. 17917 1 3 H 0.06 0.06 0.20 0.25 2 4 1 1 1 5 H 0.06 0.06 0.25 0.25 1 2 2 2 2 1 B 0.03 0.03 0.25 0.25 1 2 1 2S. pyogenes 203 0.5 0.5 4 16 0.125 0.125 16 16 891 0.5 0.5 4 16 0.06 0.06 16 16 7948 15 0.5 0.5 4 16 0.25 0.125 16 16S. pneumonlas Type I 0.25 0.25 2 2 0.06 0.06 16 16 Type III 0.5 0.5 4 4 0.125 0.125 0.06 16S. faecalls 11700 0.25 0.25 1 1 64 64 1 125 4510 0.125 0.125 0.5 0.5 64 64 2 125 8043 0.25 0.5 1 2 125 125 1 125S. enterocous 0 2 13 0.25 0.25 2 2 8 8 0.25 16E. Coll Vogel 0.25 0.5 2 2 190 0.5 0.5 2 2 8739 0.25 0.25 0.5 0.5 AB719 0.25 0.25 0.5 0.5 2350 0.25 0.25 0.5 0.5P. aeruginosa MGN 2 16 16 8 16 7700 16 16 16 16 15447 16 16 16 16 9027 4 16 8 16 27847 16 16 16 16 ATCC NO. SHRT No. TABLE 2 Inhyibitory MIC and Bactericidal MBC Values MIC mcg ml MBC mcg ml Bacteria No. Tested Compound 50 90 Range 50 90 RangeS. aureus 15 Win 52,522 0.015 0.03 0.008 0.03 0.03 0.03 0.015 0.06 Win 35.439 0.06 0.125 0.03 0.125 0.25 0.5 0.125 0.5 Methicillin 2 8 1 125 4 64 2 64 Vancomycin 1 1 0.5 1 1 1 0.5 1S. epidermidis 5 Win 52,522 0.06 0.06 0.03 0.06 0.06 0.06 0.03 0.125 Win 35.439 0.25 0.25 0.25 0.5 0.25 0.25 0.25 Methicillin 2 4 1 4 4 4 2 4 Vancomycin 1 1 1 2 1 2 1 2Streptococcus sp. 9 Win 52,522 0.25 0.5 0.125 0.5 0.5 0.5 0.125 0.5 Win 35.439 2 4 0.5 4 2 16 0.5 16 Methicillin 0.25 64 0.06 125 0.125 64 0.06 125 Vancomycin 2 16 0.06 16 16 125 16 125E. coli 5 Win 52,522 0.25 0.25 0.25 0.5 0.25 0.5 0.25 0.5 Win 35,439 0.5 2 0.5 2 0.5 2 0.5 2P. aeruginosa 5 Win 52,522 16 16 4 16 16 16 16 Win 35,439 16 16 8 16 16 16 16 16 From Table 1 it can be seen that Win 52,522 was bactericidal for all the Gram positive and Gram negative test strains MBC MIC 4 . Win 35,439 was bacteriostatic against the 3 strains of S. pyogenes. Although less potent than Win 52.522, methicillin was also bactericidal for the Gram positive cocci, while vancomycin was bacteriostatic for one strain of S. pneumoniae and all 4 strains of S. faecalis. Relative to Win 35,439, Win 52,522 was 2 to 8 times more potent in vitro against the Gram positive cocci and E. coli. and similarly potent against P. aeruginosa. These results are consistent with in vivo mouse protection tests where Win 52,522 was 3.6 s.c. to 3.9 p.o. times more efficacious than Win 35,439 against an S. aureus, and 2.6 s.c. to 2.0 p.o. times more efficacious against an E coli infection Experiment 3 hereinbelow . Win 52,522 was 32 to 8000 times more potent in vitro than methicillin against the Staphvlococcus species, 32 to 500 times more potent than methicillin againstS. faecalis, but was 2 to 8 times less potent than methicillin against S. Neogenes dnd S. pneumoniae. Win 52,522 was 16 to 125 times more potent in vitro than vancomycin against the Gram positive cocci with two exceptions 1 Win 52,522 was 8 times less potent than vancomycin against S. pneumoniae tv,e III and, 2 was equal in potency against the one enterococcus strain 0 2 B tested. The in vitro test results here support the results from an in vivo test showing Win 52,522 to be 16 and 91 times more efficacious than vancomycin and methicillin, respectively, against a methicillin resistantStaphylococcus aureus infection in mice. From the in vitro results reported here and the in vivo results shown hereinbelow Experiment 3 , it follows that Win 52,522 should be even more effective than vancomycin in killing deep seated staphylococcal tissue infections. Vancomycin is an alternate drug of choice for penicfllinase producing S. aureus The Choice of Antimicrobial Drugs, Medical Letter, March 5, 1982 and the drug of choice for the treatment of methicillin resistant Staphylococcus aureus tMethicillin resistant Staphylococcus aureus. United States Morbiditv and Mortality Weekly Report, November 20, 1981, Vol. 30, No.45, 5571. Experiment 2ANTIMICROBIAL ACTIVITY OF WIN 52,522, WIN 35,439, ROSOXACIN, NORFLOXACIN, PEFLOXACIN AND TETRACYCLINE AGAINSTANAEROBIC AND MICROAEROPHILIC BACTERIA ASSOCIATED WITH ORAL INFECTIONSSummary Win 52,522 was found to have high activity against all thirteen of the target anaerobic microorganisms and compared favorably with tetracycline, the current antibiotic of choice. Introduction It is generally accepted that certain microorganisms are the primary etiologic agents in the initiation of periodontal diseases Socransky et al.,Present Status of Studies on the Microbial Etiology ofPeriondontal Diseases, pp. 1 14. In R. Genco and S.Mergenhagen Ed. , Host Parasite Interactions in Periodontal Diseases, 1982, Amer. Soc. Micro. Washington,DC. Furthermore, there is increasing evidence to support the hypothesis that specific microorganisms are associated with each of the various forms of periodontal disease Socransky et al., supra . Accordingly, the rationale has been advanced for the use of antimicrobials in the prevention, control and treatment of these pandemic diseases. There is evidence in various animal models that the administration of various antibiotics can reduce the clinical signs of gingivitis and also decrease the.progression of alveolar hone loss associated with aggressive periodontal diseases Gibson, Antibiotics and Periodontal Disease Selective Review, J. Amer. Dent.Assoc. 104, 213 218 1982 . In man, the data would also appear supportive of the argument that antimicrobial agents are extremely useful in treating established disease, particutarly when used to augment conventional therapies Gibson, supra . In this regard, the antibiotics tetracycline and metronidazole have been shown to be partic ularly useful Genco, Antibiotics in the Treatment ofHuman Periodotal Diseases. J. Periodontol. 52, 545 558 1981 3 however, these agents do not appear to be ideal since they are not active against all the microorganisms considered to participate in the disease process.Furthermore, there are an increasing number of reports indicating that many of the so called primary pathogens of periodontal disease have already evidenced patterns of increased tolerance to these agents lGibson, supra, Genco, supra and Williams et al., Subgingival Microflora ofPeriodontal Patients On Tetracycline TheraDvl J. Clin.Periodontol. 6, 210 215 1979 . Hence, there exists an important and timely need to discover and develop new antimicrobial agents which will have utility in the prevention management of periodontal diseases. The studies described herein show that Win 52,522 was found to be extremely active against a number of anaerobic microorgan isms associated with periodontal diseases. Microorganisms The mic roorganisms used in these studies are listed in Table A hereinbelow.Culture Conditions 1. Maintenance. Prior to use, all strains were maintained in the lyophilized state. During the study, cultures were examined on blood agar basal medium supplemented with 5.0 v v defibrinated rabbit blood. Culture transfer was accomplished weekly with all cultures being incubated in an anaerobic atmosphere GasPak jar BBL . 2. Aqar Medium. The basal test medium consisted of trypticase soy agar 40 g , yeast extract 1 g , glucose 2 g and 960 ml of distilled water pH 7.2. Mashimo et al., J. Clin. Micro. 17, 187 191 1983 . Subsequent to sterilization and coolinq to 500C., the medium was supplemented with 4 v v defibrinated rabbit blood and 0.5 rg ml menadione vitamin K3 . The agent under evaluation was also added at this time to the concentration desired. Subsequent to pouring of the plates, they were permitted to dry at 40C. for 24 br. 3. Determination of Agent MIC. The minimal inhibitory concentration MIC of the various test agents was determined using an aqar dilution technique. Agents and appropriate reference compounds were added to achieve a series of concentrations ranging between 32 ug ml and 0.007 g ml. The inocula were prepared from 96 hr. cultures grown on the maintenance medium. Subsequent to a purity evaluation, colonies were removed and suspended in trypticase soy broth supplemented with 5 g ml menadione and 2 lysed rabbit blood filtrate to achieve anOD650 of 0.1 this corresponded to aprroximately 108 cells ml . Cultures were inoculated aerobically on the modified trypticase soy blood agar plates by use of aSterr s replicator which delivers about 105 cells per spot .The plates were allowed to dry for a time not exceeding 30 min. and then incubated at 370C. under an atmosphere of 80 N2, 10 , H2 and 59 C02 main an anaerobic chamber Coy Manufacturing Co. for 48 hr.The MIC was defined as the lowest concentration completely inhibiting growth.Agents Tetracycline stock solutions 1 mg ml were made subsequent to dissolution in water. Stock solutions 1 mq ml of the remaining test compounds were made subsequent to dissolution in 1 10 N NaOH. Appronriate controls indicated at the levels used NaOH did not affect the viability of the test microorganisms.Results The antimicrobial activities of the compounds tested are shown in Table A. TABLE A SUSCEPTIBILITY OF SELECTED ANAEROBIC MICROORGANISMS TO TEST COMPOUNDS Win Number g ml MICROORGANISMS 35,213a 35,439b 52,522c 9,424d 50,297e 50,150fF. polymorphum 10 4 0.5 0.12 10 8A. Viscosus 10 8 1.0 2.0 10 10B. melaninogenicus 8 8 1.0 0.5 4.0 4Caphocytophaga suptigena 1 0.5 0.06 1.0 0.5 0.25B. intermedius 0.5 0.25 0.06 2.0 0.5 0.5Eikenella corrodens 8 2.0 0.5 2.0 4.0 4.0B. oralis 10 10 4.0 0.12 4.0 4.0B. gingivalis 10 10 2.0 0.12 4.0 4.0A. actinomycetemcomitans 0.12 0.25 0.12 1.0 0.06 0.06B. fragilis 10 10 4.0 1.0 10 8.00F. nucleatum 10 4 0.5 0.75 8.00 8.00Wolinella recta 0.5 0.5 0.12 0.12 0.25Campylobacter sputorum 10 10 8.0 2.0 4.0 a Rosoxacin b 6 Desfluoro analog of win 52,522 c Applicants Exemple 2B d Tetracycline e Norfloxacin f Pefloxacin Win 52,522 is seen to be markedly superior to both Win 35,213 and 35,439.In fact, Win 52,522 showed a broad spectrum of antimicrobial activity, comPartnq favorably with the currant antibiotic of choice, tetracyeline Wins 50,297 and 50,150 were less active. x Experiment 3 IN VIVO ANTIBACTERIAL ACTIVITY OF WIN 52,522 COMPAREDTO WIN 35,439 AGAINST STAPHYLOCOCCUS AUREUS AND ESCHERICHIA COLI INFECTIONS IN MICESUMMARY Win 52,522 was determined to be more efficacious than Win 35,439, by either subcutaneous and oral routes of medication, against infections in mice produced by penicillin sensitive and methicillin resistant Stachyl ococcus aureus strains. MATERIALS AND METHODSAnimals ICR mice, female, 18 20 grams each.Antibacterial Agents Win 52,522, Win 35,439, methicillin Win 9,410 and vancomycin Win 39,556 . Bacterial Cultures Escherichia coli Vogel Staphylococcus aureus 39881 Staphylococcus aureus SmithCulture Media Brain Heart Infusion Agar Difco Brain Heart Infusion Broth Difco Gastric Mucin Bacteriological grade, Lot No. 0617,ICN Pharmaceuticals, Inc. A 5 w v suspension was prepared by adding 25 grams of gastric mucin to 475 nl of cold tap water. The suspension was mixed for 20 30 minutes with an Omni mixer, stored at 40C. overnight and just before use brought to pH 7.2 with 40 w v NaOH.Preparation of Antimicrobial Drug Solutions Solutions of Win 52,522 and Win 35.439 were prepared by dissolving the appropriate weight of drug in 0.3 to 0.4 ml of 1N NaOR and then bringing the solutions to the desired volume with distilled water. Methicillin and vancomycin were dissolved directly in distilled water.Preparation of Bacterial Cultures A. Staphylococcus aureus Smith Two and one half ml of pool were added to 247.5 ml of 5 gastric mucin to provide the test inoculum containing 2.1 x 104 cells ml. B. Staphylococcus aureus 39881 The culture was streaked onto three Brain Heart Infusion Agar plates and incubated 16 hours at 370C. The cells were washed off each plate with five ml of saline and the cell suspension was shaken with glass beads for two minutes on a paint shaker. The suspension was diluted with saline so that a 1 00 dilution gave a 44 T reading on a B L Spectroric 20 650 nm calibrated with saline. The stock suspension was diluted 1 24 10 ml stock suspension 230 ml 5 mucin to obtain the test inoculum containing 1.55 x 109 cells ml. C. Escherichia coli Vogel The culture was inoculated into 10 ml of Brain Heart Infusion broth and grown statically for 16 hours at 370C. Fresh tubes of the same broth were inoculated with Oql ml portions of the 16 hour broth culture and incubation continued for 5 hours at 370C. The 5 hour broth culture was finallv diluted with saline to provide the test inoculum containing 4.0 x 107 cells ml.Infection of Mice Mice were inoculated intraneritone ally with 0.5 ml of the bacterial test inoculum. Medication of Mice A. Staphylococcus aureus Smith 1. Single dose test Mice were medicated subcutaneously or orally once 0.5 ml one half hour postinfection. 2. Multiple dose test Mice were medicated subcutaneously 0.2 ml or orally 0.5 ml at the following times six hours and one hour preinfection infection at 2 pm and twice a day 8 a.m. and 3 30 p.m. for the next two successive days. B. Staphylococcus aureus 39881 Mice were medicated twice at one half and four hours postinfection.The drugs were administered by both subcutaneous 0.2 ml and oral 0.5 ml routes. C. Escherichia coli Vogel Mice were medicated subdutaneously or orally once 0.5 ml one half hour post infection. Deaths were recorded daily for seven days for all tests. Fifty percent protective dose values PD50 s were calculated using probit analysis SAS Users Guide Statistics. 1982 Edition, SAS Institute. Inc., Cary,North Carolina . RESULTS The in viv antibacterial activity of Win 52,522, as compared to Win 35,439, against a Staphvlococcus aureusSmith infection in mice is shown in Tables 1 and 2. TABLE 1 In Vivo Antibacterial Activity of Win 52,522 and Win 35,439 Against a Staphylococcus aureus Smith Infection in Mice Single Dose Test Protective Dose 50 Dose Survivors mg kg Drug mg kg Route Total 95 Confidence Limits Win 52,522 0.095, sc 0 10 0.8tO.6 1.1 0.19 0 10 0.39 2 10 0.78 4 10 1.56 10 10Win 35,439 0.78 sc 1 10 2.9 2.3 4.3 1.56 0 10 3.13 6 10 6.25 10 10Win 52,522 0.19 po 0 10 1.4 0.39 0 10 0.78 0 10 1.56 7 10 3.13 10 10Win 35,439 0.39 po 0 10 5.5 0.78 1 10 1.56 0 10 3.13 0 10 6.25 7 10Vancomycin 0.78 sc 2 10 1.1 0.6 1.5 1.56 9 10 3.13 9 10 6.25 10 10 12.5 10 10InfectedControls 0 20 Estimate Table 2 In Vivo Antibacterial Activity of Win 52,522 and Win 35,439 Against a Staphylococcus aureus Smith Infection in Mice Multiple Dose Test Protective Dose 50 Dose Survivors mg kg Drug mg kg Route Total 95 Confidence Limits Win 52,522 0.19 sc 0 10 1.8fl.3 2.4 0.39 z 39 0 10 0.78 0 10 1.56 4 10 3.13 9 10 6.25 10 10 12.5 10 10Win 35,439 3.13 sc 1 10 7.1 5.4 10.2 6.25 3 10 12.5 10 10 25 10 10Win 52,522 0.19 po 0 10 2.1 3.6 2.7 0.39 0 10 0.78 0 10 1.56 2 10 3.13 9 10 6.25 10 10 12.5 10 10Win 35,439 3.13 po 0 10 7.2 5.4 9.6 6.25 4 10 12.5 9 10 25 10 10InfectedControls 0 20Win 52,522 was 3.6 sc and 3.9 po times more efficacious than Win 35,439 when administered as a single dose one half hour postinfection.Win 52,522 was 3.9 sc and 3.4 pro times more efficious than Win 35,439 against the same infection when given in a multiple dose reqimen. PD50 values within 52,522 aqainst a methicillin resistant Staphylococcus aureus infection in mice were 1.1 and 1.6 mg kg for subcutaneous and oral medication, respectively, as shown in Table 3. Table 3 In Vivo Antibacterial Activitv of Win 52,522, Win 35,439, Methicillin and Vancomycin Against a Staphylococcus aureus 39881 Methicillin resistant Infection in Mice Protective Dose 50 Dose Survivors mg kg Drug mg kg Route Total 95 Confidence Limits Win 52,522 0.19 sc 0 10 1.1 0.1 4.1 0.39 0 10 0.78 2 10 1.56 10 10 3.13 9 10 6.25 10 10Win 35,439 1.56 sc 0 10 3.13 0 10 6.25 9 10 12.5 7 10Win 52,522 0.19 po 0 10 1.6 1.3 2.4 0.39 0 10 0.78 1 10 1.56 4 10 3.13 10 10 6.25 10 10Win 35,439 1.56 po 1 10 7.2 5.6 10.0 3.13 0 10 6.25 3 10 12.5 10 10Methicillin 25 sc 0 10 100 50 0 10 100 0 10Vancomycin 6.25 sc 0 10 17.7 13.8 22.6 12.5 1 10 25 9 10 50 10 10InfectedControls 0 20 Estimate Two doses one half and four hours postinfection Win 52,522 sc was 4.5 and 16 times more that infection than Win 35,439 and vancomycin, respectively. The in vivo activity of Win 52,522 and 35,439 against an Escherichia coli Vogel infection in mice is shown in Table 4. Table 4In Vivo Antibacterial Activity of Win 52,522 and Win 35,439 Against a Escherichia coli Vogel Infection in Mice Protective Dose 50 Dose Survivors mq kq Drug mg kg Route Total 95 Confidence Limits Win 52,522 1.56 sc 0 10 5.2 3.13 0 10 6.25 8 10 12.5 10 10 25 10 10Win 35,439 3.13 sc 1 10 13.5 10.5 19.2 6.25 0 10 12.5 4 10 25 1.0 10 Win 52,522 1.56 po 0 10 8.2 6.3 10.8 3.13 0 10 6.25 2 10 12.5 9 10 25 10 10Win 35,439 3.13 po 0 10 16.5 12.6 21.8 6.25 0 10 12.5 2 10 25 9 10 InfectedControls 0 20 Estimate Subcutaneous and oral PD50 values of Win 52,522 against that infection were 5.2 and 8.2 mg kg., approximately one half those of Win 35,439. The results of this studv demonstrate that Win 52,522, by both parenteral and oral medication routes. is a very potent antibacterial agent against infections in mice produced by both penicillin sensitive and methicillin resistant Starhylococcus aureus strains. The compound of formula I or a pharmaceutically acceptable non toxic acid addition or cationic salt thereof can be prepared for use by conventional pharmaceutical procedures that is, bv dissolving or suspending them in a pharmaceutically accePtable vehicle, e.g., water, aqueous alcohol glycol, oil solution or oil water emulsion, for parenteral or oral administration or by incorporating them in unit dosage form as capsules or tablets for oral administration either alone or in combination with conventional adjuvants or excipients, e.g., calcium carbonate, starch, lactose, talc, magnesium stearate, gum acacia, and the like.